Ascletis claims its oral ASC36_35 FDC outperforms eloralintide/tirzepatide combo in preclinical obesity model, positioning it as a potential next‑generation weight‑loss therapy
Executive summary: Ascletis Pharma presented preclinical data showing its oral ASC36_35 fixed-dose combination achieved greater weight loss than the eloralintide/tirzepatide combination in a diet‑induced obese mouse model, with results to be discussed orally at the EASD 2026 meeting. The finding suggests a potentially more effective oral alternative to current injectable obesity therapies, which could shift competitive dynamics in the fast‑growing anti‑obesity drug market.
Who is involved: Ascletis Pharma Inc. (HKEX:1672), its research team, and the comparator drugs eloralintide and tirzepatide.
Likely next: The company plans to conduct GLP toxicology studies and pursue an IND filing, while exploring partnership or licensing opportunities with larger pharmaceutical firms.
Ascletis Pharma disclosed that its oral fixed-dose combination ASC36_35 produced superior weight loss versus the eloralintide/tirzepatide pair in a diet‑induced obese mouse model. The data were slated for oral presentation at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting in July 2026. No human safety or efficacy data were included in the announcement.
Timeline
- — Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting (PR Newswire)
- — Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026 (GlobeNewswire)
Analysis — what this means
Sectors affected
- Anti-obesity therapeutics
- GLP-1/GIP receptor agonist market
Historical parallels
- FDA approval of semaglutide (Wegovy) for chronic weight management in 2021
- Tirzepatide (Mounjaro) demonstrated significant weight loss in phase 3 trials in 2022
Key entities
Sources
- Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting — PR Newswire
- Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026 — GlobeNewswire